Kane Biotech Receives Funding Support to Expand the revyve™ Antimicrobial Wound Gel Family
WINNIPEG, Manitoba, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”)...
News
Crescent Innovations reports strong interest in asset sale
WESTFORD, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Crescent Innovations Inc. reports that activity surrounding sale of its joint, bone...
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Expansion of the Phase 2b MOVE-IT Study of Naronapride in Gastroparesis and Dosing of the First United States Patient
ROSCREA, Ireland and FREIBURG, Germany, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed...
Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization
The ISO 13485 certification is a validation of the Company’s robust quality systemBRAINTREE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) --...
Intelligent Bio Solutions Inc. Highlights Growing Need for Drug Testing Solutions in Key Industries
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) provides an overview of the increasing...
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
Company to Focus on Targeted Promotion of INPEFA® in Heart Failure While Prioritizing Investment in the Potential Launch of ZYNQUISTA™...
Ocean Drive Plastic Surgery Introduces Revolutionary Internal Sports Bra Procedure for Athletes and Fitness Enthusiasts
Dr. Alan Durkin, a dual board-certified plastic and reconstructive surgeon and the founder of Ocean Drive Plastic Surgery in Vero...
COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone...
Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of...
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase...
Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results
GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10...
Notice of Nexstim Plc’s Half-Year Report H1 2024
Press release, Helsinki, 13 August 2024 at 3 PM (EEST) Notice of Nexstim Plc’s Half-Year Report H1 2024 Nexstim Plc...
Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that...
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin...
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with...
ViaDerma Announces Shipment of 500,000 Units of its Flagship Product to Nigeria
LOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a leader in innovative wound care solutions, is...
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones
First-in-class catheter-based sensing and ablation technology that targets neural signals that indicate pain or disease and destroys them at the...
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
Appointed Dr. Amanda Banks, a tenured physician and biotech leader, as Chief Development Officer to lead clinical strategy and executionExpanded...
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial...